VK2809 in NAFLD

VK2809 in NAFLD: a phase 2 study
Loomba R, AASLD 2018, Abs. LB4




  • VK2809: selected liver-targeted thyroid receptor β agonist


  • Primary: change in LDL-cholesterol vs placebo
  • Secondary: change in liver fat by MRI-PDFF
  • Exploratory: changes in atherogenic lipoproteins

Baseline characteristics

Placebo-Adjusted % Change in LDL-C at W12

Relative change in MRI-PDFF liver fat content at W12, %

Absolute change in MRI-PDFF liver fat content at W12, %

  • 66.7% of patients treated with VK2809 experienced a ≥ 50% decrease in liver fat content vs 18.2% in placebo-treated patients

Change in Lipoprotein(a) at W12, %

Change in Apolipoprotein B at W12, %

Summary of adverse events

  • Good tolerability and safety
  • No serious adverse events observed in any arm
  • No dose-related trends in AEs
  • Excellent gastro-intestinal tolerability


  • VK2809 produced robust reduction in liver fat on MRI-PDFF in NAFLD patients after 12 weeks of oral dosing
  • Up to 91% of patients dosed with VK2809 experienced a response as demonstrated by liver fat reductions ≥ 30% relative to baseline ; 67% experienced liver fat reductions ≥ 50%
  • VK2809 produced significant reduction in LDL-C, triglycerides, Apo B, and Lp(a) relative to placebo in NAFLD patients
  • VK2809 was safe and well-tolerated